Darlene Dobkowski, MA

Watch Dr. Beverly Moy, from Massachusetts General Hospital, discuss addressing breast cancer disparity during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Dejan Juric, from Massachusetts General Hospital, discuss therapeutic resistance during the CURE Educated Patient Metastatic Breast Cancer Summit.

One expert said that the FDA approval of the antibody-drug conjugate Elahere represents a new treatment option for patients with folate receptor alpha-positive, platinum resistant ovarian cancer.

Identifying genetic mutations in lung cancer has allowed researchers to develop treatments that target specific biomarkers over the past 20 years, but more research is needed to further the space.

Patients should describe their symptoms in detail and seek early care for suspected lung cancer, especially since the disease may resemble pneumonia and bronchitis on imaging tests.

Imjudo, Imfinzi and chemotherapy improved overall and progression-free survival in certain patients with non-small cell lung cancer.

Stem cell transplants may cause dysgeusia — a disorder that alters a person’s taste —in some patients with multiple myeloma, which is a type of blood cancer. This disorder may have a domino effect on quality of life, although levels may return to normal a few months after the procedure, an expert said.

Compared with tissue biopsies, liquid biopsies performed with blood samples may inform cancer teams of a patient’s increased risk for blood cancers, although all patients may not have this risk.

Advocacy groups helped one patient with ocular melanoma — and many others — learn more about their disease and treatment, as well as a place to connect about their experiences.

The dual immunotherapy regimen of Imjudo and Imfinzi may provide patients with unresectable hepatocellular carcinoma a well-tolerated treatment to extend survival.

Watch Dr. Jared Weiss, from UNC School of Medicine, discuss neoadjuvant versus adjuvant therapy during the CURE Educated Patient Lung Cancer Summit.

The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.

Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for these patients.

Radiotherapy with standard of care for the treatment of patients with low-burden metastatic prostate cancer had minimal effects on quality of life over a five-year follow-up period.

Adding the investigational cancer drug lanraplenib to Xospata, if found to be effective, may broaden treatment options for patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.

In less than a year, Christine Whelchel went from receiving a diagnosis of breast cancer to becoming a trailblazing “Jeopardy!” champion.

Care teams often implant a chemo port into patients with cancer to provide easy access for blood draws and to deliver treatments such as chemotherapy and antibiotics. Here, as part of its Heal at Home series, CURE® works with a nurse to provide a guide for patients to care for their port.

One patient turned her diagnosis of multiple myeloma into a way to educate others as an advocate.

Experts from Cancer Treatment Centers of America explain why mental health is important from cancer diagnosis through survivorship, the types of therapy and more.

The results, according to the study authors, may highlight a bigger issue related to structural racism in health care.

Patients with stage 3 colon cancer who consume processed meat or unprocessed red meat after receiving their diagnosis may not be at an increased risk for cancer recurrence or death.

Researchers have treated the first patient in the PRECISION 1 trial with Fyarro to assess the drug’s efficacy across several endpoints including survival among more than 100 patients with solid tumors that exhibit certain genetic alterations.

The plan is to assess the safety and efficacy of the genetically engineered cell therapy alongside high-dose chemotherapy and blood stem cell transplantation in approximately 150 patients with lymphoma.

“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of immunotherapy from palliative treatment in the metastatic setting to curative treatment in localized disease,” the study authors wrote.

A patient with an advanced solid tumor was given their first dose of a novel antibody, kicking off a phase 1/1b study comparing this drug with or without Keytruda in patients with several types of solid tumors.

Certain patients with metastatic breast cancer may benefit from Enhertu compared with standard of care with Kadcyla despite higher rates of side effects including lung inflammation and interstitial lung disease.

Watch Dr. Noa Biran, an associate professor of medicine in the division of multiple myeloma at The John Theurer Cancer Center at Hackensack University Medical Center, discuss treatment for relapsed/refractory myeloma.

Watch Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center discuss treatment for newly diagnosed myeloma.

Treatment with a novel monotherapy in a patient with relapsed/refractory acute myeloid leukemia was effective enough that a successful, as indicated by a significant reduction in bone marrow blasts, stem cell transplant was performed.

As a patient moves from treatment to survivorship, the fear of cancer recurrence may overshadow the ability for them to recognize how much they have endured, but support is available to hopefully lessen the burden.